Plain-English translation of NCT06166654 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether two medications called and metolazone can help treat acute heart failure with fluid overload better than standard treatment alone. Patients hospitalized with heart failure often struggle to remove excess fluid from their body, and this study wants to find out if either of these two water pills — added to the usual diuretic (water pill) treatment — works better than the standard approach.
Heart failure patients frequently develop a resistance to standard water pills, meaning the usual treatment doesn't remove enough fluid from their bodies. This trial exists to find a better way to help these patients get rid of dangerous fluid buildup during hospitalization.
You likely qualify if…
You likely don't qualify if…
If you qualify, you'll be randomly assigned to receive either (given as an injection), metolazone (taken as a tablet), or standard treatment only — all while hospitalized for heart failure. You'll receive your assigned treatment once when you join the study and then each morning for the next three days. Doctors will monitor how much fluid you lose and how you feel throughout your hospital stay.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
Denmark